Pulmatrix Inc (PULM)

[riskon]

$PULM Catalysts: (non-exhaustive)
1) PUR1900 FDA Type C Meeting Results, Initiation of P2B/P3 Trial for ABPA
2) Results of Renegotiation of terms with Cipla on PUR1900 (regain US/Europe rights in full)
3) PUR1800 - Trial update / news
4) PUR1800 JnJ $90M option exercising
5) PUR3100 Update / Development Partnership announcement (we know Cipla is likely involved, via the DHE 45 route)
6) FEND - Wide variety of updates, including potential government contracts / future studies / worldwide organizational alliance
7) Nocion Therapeutics partnership update
8) Speculative but all have grounds:
*PUR1900 LPAD / EUA pathway for ABPA in CV-19 patients
*PUR1900 combination w/ other pharmaceuticals for other indications (cancer, covid-19, etc.)
*PUR1800 - Repurpose for Cytokine storm therapeutics
*Collaboration with SIWA Therapeutics
*Collaboration with Nob Hill Therapeutics
*Inhaled Vaccine trials (JnJ)
*Alternative partnerships for iSPERSE development
*Additional